Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / V••••••• C••••••• T•••••

F••••••• R••••••• Establishes Meaningful Presence in Oncology with Strategic Investment in V••••••• C••••••• T•••••

Add-on acquisitionannouncedadd-onannounced Oct 6, 2025Fact
What happened
Target
V••••••• C••••••• T•••••
Platform
F••••••• R•••••••add-on basis: Scott Niehaus, Managing Director at G•••••• C••••••, which acquired F••••••• in 2024, commented, “Dr. Berz and his team have built a highly impressive and innovative business in one of the most attractive areas of clinical research.
Control
Control
Share acquired
unknown
Industry
healthcare / clinic
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
7 named
Buy side
  • F••••••• R•••••••Platformconfirmed
    “Scott Niehaus, Managing Director at G•••••• C••••••, which acquired F••••••• in 2024, commented, “Dr. Berz and his team have built a highly impressive and innovative business in one of the most attractive areas of clinical research.”
  • G•••••• C••••••Sponsorconfirmed
    “Scott Niehaus, Managing Director at G•••••• C••••••, which acquired F••••••• in 2024, commented, “Dr. Berz and his team have built a highly impressive and innovative business in one of the most attractive areas of clinical research.”
Advisory side
  • S••••••• M•••••Legal adviserconfirmed
    “H••••••• L•••• served as exclusive financial advisor and S••••••• M••••• provided legal counsel to V•••••••.”
  • R•••• • G••• L••Legal adviserconfirmed
    “R•••• • G••• L•• provided legal counsel to F•••••••.”
  • H••••••• L••••Sell-side adviserconfirmed
    “H••••••• L•••• served as exclusive financial advisor and S••••••• M••••• provided legal counsel to V•••••••.”
Side not stated
Evidence
“F••••••• R••••••• Establishes Meaningful Presence in Oncology with Strategic Investment in V••••••• C••••••• T•••••”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026
F••••••• R••••••• Establishes Meaningful Presence in Oncology with Strategic Investment in | Private Equity Intelligence | DFX